WA-SCHULTZ-FAMILY-FND
Trilogy Films, the renowned production company led by award-winning Director Dawn Porter, is thrilled to announce an unprecedented collaboration with the Schultz Family Foundation to produce a feature-length documentary about one of the most iconic, politically-charged partnerships in history: the remarkable, largely untold story of Nelson and Winnie Mandela.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240212248716/en/
Nelson and Winnie Mandela after his liberation from prison in South Africa on February 11, 1990. Photo by Pool BOUVET/DE KEERLE/Gamma-Rapho via Getty Images.
Based on the book by noted South African writer and scholar Jonny Steinberg, Winnie and Nelson: Portrait of a Marriage, the film will explore the Mandelas’ profound bond and how their marriage was inextricably entangled with the struggle against apartheid. The film promises an intimate portrayal of Nelson and Winnie’s marriage, delving into their vehement and volatile connection from their early years to their mutual goal of dismantling apartheid. Their journey culminates in Nelson Mandela’s historic election as South Africa’s first democratically elected President. This cinematic exploration captures the essence of their indomitable spirits and the global impact of their love and advocacy.
Dawn Porter, celebrated for her exceptional storytelling that explores the overlooked, reveals the consequences of policy and social action, champions the marginalized, and offers a fresh perspective on the familiar, is at the helm of the production. With her profound ability to craft narratives that deeply resonate with and inform audiences, Porter is poised to bring a unique lens to the enduring love story of Nelson and Winnie Mandela.
“Creating a film about Nelson Mandela’s life is an extraordinary privilege, and I am genuinely thrilled about the collaboration with the Schultz Family Foundation and Trilogy Films,” said Dawn Porter. “Nelson Mandela’s journey exemplifies the resilience and capacity for change within the human spirit. We aspire to share this incredible odyssey with audiences around the globe. But his story is incomplete without exploring the relationship with his most influential and intimate advisor – his wife Winnie. There can be no definitive Mandela story without understanding the complicated dynamics of their relationship.”
The collaboration with Trilogy Films marks the Schultz Family Foundation’s first venture into transformative storytelling projects – across scripted and documentary films and series, podcasts, and books – linked to its mission of creating greater opportunity, accessible to all. The Schultz Family Foundation’s involvement transcends financial support; it embodies a philanthropic vision and commitment to tell truthful, aspirational stories that have the power to reveal hidden narratives, spark hope, spotlight solutions, and restore confidence during a time of enormous pessimism, dissension, misinformation, and a fracturing of trust in traditional institutions, leadership, and each other.
“At its heart, Winnie and Nelson is a complicated story of leadership, conflict, love, and extraordinary sacrifice in the face of unfathomable brutality where the future of a democracy was at stake,” said Howard Schultz, co-founder of the Schultz Family Foundation and chairman emeritus of Starbucks Corporation. “My wife Sheri and I feel privileged and humbled by the opportunity to partner with such a respected and talented director as Dawn to bring this film to life. We believe in the power of human-centered, aspirational storytelling to nurture our common bonds, foster our shared humanity, and inspire the next generation of leaders, and we look forward to pursuing other projects across many different formats aligned with our family’s philanthropic work and mission.”
About Trilogy Films:
Trilogy Films, founded by award-winning director Dawn Porter, directs and produces non-fiction content that tells untold stories, shares new perspectives, and reveals the complex humanity of some of history’s most iconic figures. Porter's acclaimed films include "Gideon’s Army" (2013), "Spies of Mississippi” (2014), and “Bobby Kennedy for President” (2018). Her latest work, “Luther: Never Too Much,” debuted to rave reviews at the 2024 Sundance Film Festival and was lauded as the best of fest in multiple news outlets. 2023 was a banner year for Porter and Trilogy. The Critics Choice nominated “Lady Bird Diaries," an all archival documentary showcasing Lady Bird Johnson, premiered at the 2023 SXSW Film Festival, while her four-part docuseries "Deadlocked: How America Shaped the Supreme Court” also garnered nominations for a Critics Choice Documentary Award as well as a Film Independent Spirit Award.
About the Schultz Family Foundation:
The Schultz Family Foundation’s mission is to create greater opportunity, accessible to all. Our work is deeply rooted in the lives and values of our co-founders, Sheri and Howard Schultz, who believe talent is everywhere, but opportunity is not. We seek to apply the lessons they have learned over the decades to seed innovations and scale solutions to help young people successfully navigate the transition to adulthood and positively impact the trajectory of their lives. We are investors in unleashing potential and unlocking opportunity, working in partnership with employers, entrepreneurs, non-profits, and governments that share our aspiration of enabling everyone to access the full promise of America. For more information about the Foundation and its work: www.schultzfamilyfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212248716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
